復星醫藥(02196.HK)夥控股股東等設基金投資醫療器械等
復星醫藥(02196.HK)公布,附屬公司大連復健、寧波復瀛,公司控股股東復星高科技、大連融達及旅順國投共同設立基金,計劃募集資金為5億元人民幣,基金主要參股投資醫療器械、醫療科技及相關產業的初創期創新型、早中期創新型企業。
大連復健、寧波復瀛、復星高科技、大連融達及旅順國投分別出資500萬元、2億元、5,000萬元、1.45億元和1億元,各佔合夥權益1%、40%、10%、29%和20%。公司附屬復健基金將獲委託作為目標基金的基金管理人,該基金、大連復建及復健基金,將就該基金的相關基金管理事宜訂立目標基金管理協議,為期3年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.